Dynavax Technologies Corporation (DVAX): Price and Financial Metrics

Dynavax Technologies Corporation (DVAX): $14.38

0.03 (-0.21%)

POWR Rating

Component Grades








Add DVAX to Watchlist
Sign Up

Industry: Biotech




#52 of 356

in industry

DVAX Price/Volume Stats

Current price $14.38 52-week high $15.12
Prev. close $14.41 52-week low $9.42
Day low $14.21 Volume 427,036
Day high $14.48 Avg. volume 1,525,657
50-day MA $14.22 Dividend yield N/A
200-day MA $12.03 Market Cap 1.85B

DVAX Stock Price Chart Interactive Chart >


  • DVAX scores best on the Value dimension, with a Value rank ahead of 90.35% of US stocks.
  • DVAX's strongest trending metric is Quality; it's been moving up over the last 177 days.
  • DVAX's current lowest rank is in the Growth metric (where it is better than 0.25% of US stocks).

DVAX Stock Summary

  • With a price/sales ratio of 3.82, DYNAVAX TECHNOLOGIES CORP has a higher such ratio than 74.23% of stocks in our set.
  • In terms of twelve month growth in earnings before interest and taxes, DYNAVAX TECHNOLOGIES CORP is reporting a growth rate of -50.52%; that's higher than 25.38% of US stocks.
  • As for revenue growth, note that DVAX's revenue has grown -31.82% over the past 12 months; that beats the revenue growth of merely 8.23% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to DYNAVAX TECHNOLOGIES CORP, a group of peers worth examining would be BL, PWSC, DOCS, CHGG, and SWAV.
  • DVAX's SEC filings can be seen here. And to visit DYNAVAX TECHNOLOGIES CORP's official web site, go to www.dynavax.com.

DVAX Valuation Summary

  • In comparison to the median Healthcare stock, DVAX's price/sales ratio is 100% higher, now standing at 3.8.
  • Over the past 238 months, DVAX's price/sales ratio has gone down 265.6.

Below are key valuation metrics over time for DVAX.

Stock Date P/S P/B P/E EV/EBIT
DVAX 2023-09-22 3.8 3.0 15.9 14.9
DVAX 2023-09-21 3.8 3.1 16.0 15.0
DVAX 2023-09-20 3.8 3.0 15.7 14.8
DVAX 2023-09-19 3.8 3.1 16.0 15.0
DVAX 2023-09-18 3.8 3.0 15.8 14.9
DVAX 2023-09-15 3.8 3.0 15.9 15.0

DVAX Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at -2.9%.
  • Its year over year cash and equivalents growth rate is now at 126.58%.
  • Its 4 year net income to common stockholders growth rate is now at -16.33%.
DVAX's revenue has moved up $698,042,000 over the prior 33 months.

The table below shows DVAX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 733.261 148.265 320.633
2022-06-30 673.796 152.916 228.394
2022-03-31 470.099 247.053 104.112
2021-12-31 439.442 335.528 72.144
2021-09-30 263.922 199.288 -38.533
2021-06-30 169.066 105.256 -5.702

DVAX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DVAX has a Quality Grade of B, ranking ahead of 88.86% of graded US stocks.
  • DVAX's asset turnover comes in at 0.367 -- ranking 129th of 681 Pharmaceutical Products stocks.
  • LJPC, ABT, and CVM are the stocks whose asset turnover ratios are most correlated with DVAX.

The table below shows DVAX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.367 0.719 0.023
2021-03-31 0.312 0.715 -0.092
2020-12-31 0.144 0.701 -0.128
2020-09-30 0.123 0.612 -0.182
2020-06-30 0.119 0.519 -0.278
2020-03-31 0.146 0.505 -0.263

DVAX Price Target

For more insight on analysts targets of DVAX, see our DVAX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.50 Average Broker Recommendation 1.38 (Strong Buy)

Dynavax Technologies Corporation (DVAX) Company Bio

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, using TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. The company was founded in 1996 and is based in Berkeley, California.

DVAX Latest News Stream

Event/Time News Detail
Loading, please wait...

DVAX Latest Social Stream

Loading social stream, please wait...

View Full DVAX Social Stream

Latest DVAX News From Around the Web

Below are the latest news stories about DYNAVAX TECHNOLOGIES CORP that investors may wish to consider to help them evaluate DVAX as an investment opportunity.

Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 73.92%: Read This Before Placing a Bet

The consensus price target hints at a 73.9% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | September 29, 2023

Here's What Could Help Dynavax Technologies (DVAX) Maintain Its Recent Price Strength

Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Yahoo | September 29, 2023

Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why

Crinetics (CRNX) surges 69.6% in a month due to encouraging results from its late-stage study, paltusotine, in patients with acromegaly who were switching from current standard-of-care treatment.

Yahoo | September 28, 2023

Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent

Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.

Yahoo | September 28, 2023

Unveiling Dynavax Technologies (DVAX)'s Value: Is It Really Priced Right? A Comprehensive Guide

Exploring the intrinsic value of Dynavax Technologies Corp (DVAX) and its investment potential

Yahoo | September 26, 2023

Read More 'DVAX' Stories Here

DVAX Price Returns

1-mo N/A
3-mo 13.68%
6-mo N/A
1-year 27.71%
3-year 240.76%
5-year 35.53%
YTD 35.15%
2022 -24.38%
2021 216.18%
2020 -22.20%
2019 -37.49%
2018 -51.07%

Continue Researching DVAX

Want to see what other sources are saying about Dynavax Technologies Corp's financials and stock price? Try the links below:

Dynavax Technologies Corp (DVAX) Stock Price | Nasdaq
Dynavax Technologies Corp (DVAX) Stock Quote, History and News - Yahoo Finance
Dynavax Technologies Corp (DVAX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!